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Introduction
　Many stressors have a deleterious effect on the human circulatory system 1, 2）, including 
mental stress, which causes variability in the heart rate 3）.  The duration of shift-work is a 
stressor that is signicantly associated with changes in systolic blood pressure and cholesterol 
levels in male workers and changes in diastolic blood pressure in female nurses4）.  A simple 
activity such as a mental arithmetic task increases mean arterial blood pressure in healthy 
males 5）.  Many studies have been reported on the relationship between stressors and func-
tioning of the circulatory system including the heart, blood vessels, blood, and the lymphatic 
system6, 7, 10, 11）.  Stressors can cause hypertension and many other cardiovascular diseases 
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Abstract : The effects of stress on blood uidity may be mediated through the 
sympathetic adrenergic nervous system.  We investigated this proposition using 
a micro-channel array ow analyzer that mimics capillaries to study the effects 
of adrenergic receptor agonists and antagonists on blood fluidity in male 
Wistar rats.  An α-adrenergic receptor agonist and a β-adrenergic receptor 
antagonist reduced blood uidity whereas an α-adrenergic receptor antagonist 
and β-adrenergic receptor agonist increased blood uidity.  Both the stimula-
tory and inhibitory effects were larger when EDTA was used as an anticoagu-
lant rather than heparin.  The α-adrenergic receptor agonist enhanced platelet 
aggregation whereas and β-adrenergic receptor agonist reduced aggregation 
when citrate was used as an anticoagulant in platelet-rich plasma.  Blood 
uidity is affected by many factors including : hematocrit, platelet aggregation, 
leukocyte adhesion, and erythrocyte deformability.  EDTA blocks platelet 
aggregation by chelating calcium ions whereas heparin does not.  The hema-
tocrit was not affected by any of the adrenergic reagents we examined.  We 
propose that adrenergic receptor-modulating drugs alter blood uidity through 
changes in both platelet aggregation and erythrocyte deformability.
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but there is little information on the relationship between stressors and blood uidity.  A 
decrease in blood fluidity can also cause hypertension according to Poiseuille’s law, the 
principle that the volume of a homogeneous uid passing per unit time through a capillary 
tube is directly proportional to the pressure difference between its ends and to the fourth 
power of its internal radius, and inversely proportional to its length and to the viscosity of 
the uid, and may result in cardiac infarction8, 9）.  In this study, we investigated the relation-
ship between stressors and blood uidity using micro-channel array ow analysis （MC-FAN）. 
Restraint and electrical shock stress decreases blood uidity in rats10, 11）, which was restored 
by an α-adrenergic receptor （α-AR） antagonist9）.  Therefore we examined the effects of 
adrenergic receptor agonists and antagonists on blood uidity in rats.
Materials and Methods
Animals
　Specific pathogen-free male Wistar rats weighing approximately 100 g （4 w, Japan Bio-
Supply Center, Tokyo, Japan） were used.  The animals were kept in our animal facilities 
at 25 ± 2 ℃, a humidity of 55±5 ％, and a light and dark cycle of 12 h.  The rats were 
randomly divided into ve groups : control, α-AR agonist, α-AR antagonist, β-AR agonist, 
and β-AR antagonist groups.  Food and water were fed to the animals ad libitum.  This 
study was approved by the Ethics Committee of Showa University for Animal Experiments 
（08017）.
Sampling of blood
　Blood samples of 2.5 mL were collected from the posterior aorta under sodium pento-
barbital anesthesia at 50 mg / kg intraperitoneally （i.p.）, （Dainippon Sumitomo Pharma Co., 
Osaka, Japan）.  The blood was divided into three tubes and mixed with anticoagulants as 
follows : 1.0 mL of blood was mixed with 45 units of sodium heparin （heparin）, 0.5 mL of 
blood was mixed with 2.4 mg of dipotassium ethylene-diamine tetraacetic acid （EDTA）, and 
1 mL of blood was mixed with 32 mg of sodium citrate （citrate）.
Blood cell count
　We used an automatic blood cell counter PCE-210 （ERMA Inc., Tokyo） to measure the 
blood cell number.  Red blood cells （RBC）, white blood cells （WBC）, platelets （Plt） and 
the hematocrit were counted in EDTA-treated blood. 
Sampling of Plt-rich plasma
　The blood was centrifuged at 400×g for 5 min in a 5702R centrifuge at 25℃ （Eppendorf 
AG., Germany）.  Plt-rich plasma （PRP） was collected from the supernatant fraction of blood 
and the pellet was recentrifuged at 2300×g for 5 min at 25 ℃ to obtain Plt-poor plasma 
（PPP）.  In the PRP the number of Plt was adjusted to 3×105 /μL by diluting with PPP.
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Drugs and administration method
　We used phenylephrine （Sigma Chem. Co., St Louis, MO, USA） at 20μg / kg an α-AR 
agonist, phentolamine （Sigma Chem. Co.） at 10μg / kg as an α-AR antagonist, isoproterenol 
（Sigma Chem. Co.） at 0.4μg / kg as a β-AR agonist, and propranolol （Sigma Chem. Co.） 
at 4μg / kg as a β-AR antagonist.  These were the recommended clinical dosages for 
humans.  Four doses were used for the animal experiments : 0.1×, 1×, 10× and 100× 
relative to the clinical human dosage.  In these experiments, the drugs were dissolved in 
1 mL of saline and were administered i.p. to the rats.  Saline （1 mL） was administered i.p. 
to the control animals.  The drugs were administered 20 min after pentobarbital anesthesia 
and blood was collected 10 min after administration of the drug.  The incubation time for 
these drugs when added directly to blood in vitro was 30 min and the concentrations of 
these drugs were adjusted to the same as that used for the i.p. administration.
Measurement of blood uidity
　We used a Micro Channel Array Flow Analyzer KH-6 （MC-FAN） to measure blood 
uidity.  The MC-FAN measures the time interval for blood to pass through micro grooves 
engraved on a silicone tip.  An increase in this time interval indicates a decrease in blood 
fluidity and conversely a shortening of the time interval indicates an increase in blood 
uidity.  An aliquot of 100μL of blood that had been treated with heparin or EDTA to 
prevent coagulation was used to measure the time interval, which represented the blood 
uidity index.
Measurement of Plt aggregation
　Plt aggregation was measured using a platelet aggregometer PA-20 （Kowa Co. Ltd., Tokyo, 
Japan） that employs a novel light scattering （LS） method and a conventional light transmis-
sion （LT） method.  An aliquot of 270μL of control PRP was added to a cuvette that was 
pre-warmed to 37℃ and 30μL of ADP （100μM） was added （Oriental Yeast Co. Ltd., 
Tokyo, Japan） as an agonist of Plt aggregation.
　The Plt aggregometer determines the size of Plt aggregates by measuring the intensity of 
light （LS） scattered by a particle, which is directly proportional to the particle size.  The 
degree of platelet aggregation was expressed as the cumulative voltage of LS intensity mea-
sured at 10 s intervals.  The measured aggregates were divided into three categories according 
to their size : small （diameter 9-25μm）, medium （diameter 26-50μm）, and large aggregates 
（diameter ＞ 50μm）.  An increase in the number of large aggregates indicates an increase 
in the level of Plt aggregation.  The degree of platelet aggregation was also expressed as ％ 
turbidity, which was indicated by the difference between the ％ LT for PRP and PPP.
Statistical analysis
　Statistical analysis was performed using the “Super ANOVA” （Abacus Concepts Inc. 
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Berkley, CA, USA）.  The statistical signicance was calculated using Fisher’s Protected LSD 
as a post-hoc test.  Results were statistically signicant when P＜ 0.05. 
Results
Analysis of blood components
　In order to effectively analyze blood uidity, we examined the level of different blood 
components, which could affect the properties of blood.  The number of RBCs, WBCs, Plts, 
and the hematocrit were measured after administration of drugs to each group.  There were 
no statistically signicant differences between each group （Table 1）.
The effects of an AR agonist and an AR antagonist on blood uidity
The effects of i.p. administered adrenergic drugs
　When heparin was used as anticoagulant, the time interval for blood from the untreated 
control group was 48.73±2.69 s, for the 10×α-AR agonist-treated group was 54.25±4.30 
s, and for the 10 ×β-AR agonist-treated group was 45.04±3.19 s （Fig. 1A）.  Therefore, the 
α-AR agonist signicantly increased the time interval and the β-AR agonist signicantly 
decreased the time interval relative to the control group.  When heparin was used as an 
anticoagulant, the time interval for the control group was 48.39±2.37 s, for the 10×α- 
AR antagonist-treated group was 42.29±0.21 s, and for the 10×β-AR antagonist-treated 
group was 52.70 ± 1.52 s （Fig. 1B）.  Therefore, the α-AR antagonist signicantly decreased 
the time interval and the β-AR antagonist signicantly increased the time interval relative 
to the control group.  When EDTA was used as the anticoagulant, the time interval for the 
control group was 54.04±6.59 s, for the 10×α-AR agonist-treated group was 67.93±3.40 s, 
for 10 ×β-AR agonist-treated group was 44.44±4.20 s （Fig. 1C）.  Therefore, using EDTA, 
the α-AR agonist signicantly increased the time interval and the β-AR agonist signicantly 
decreased the time interval relative to the control group.  Again, when EDTA was used as 
the anticoagulant, the time interval for the control group was 52.02±5.16 s, for the 10×α- 
AR antagonist-treated group was 44.42±1.16 s, for the 10×β-AR antagonist-treated group 
was 61.07 ± 6.51 s （Fig. 1D）.  Therefore, using EDTA, the α-AR antagonist significantly 
decreased the time interval and the β-AR antagonist signicantly increased the time interval 
Table 1.  Blood property of each experimental group
Mean ± SE Body weight（g） PLT（104 /μL） WBC（103 /μL） RBC（106 /μL） Hct（％）
control（n＝ 7） 325.0 ± 9.70 58.9 ± 6.55 6.5 ± 1.06 6.8 ± 0.46 41.0± 3.13
αagonist（n＝ 7） 312.5 ± 13.43 60.9 ± 8.92 6.4 ± 1.30 7.1 ± 0.44 41.6 ± 1.98
βagonist（n＝ 7） 321.3 ± 14.05 63.6 ± 4.08 6.7 ± 1.42 6.8 ± 0.32 39.6 ± 2.14
αantagonist（n＝ 7） 324.2 ± 14.80 60.7 ± 0.84 5.0 ± 0.66 6.6 ± 0.36 38.9 ± 1.71
βantagonist（n＝ 7） 316.5 ± 11.45 66.0 ± 5.73 6.4 ± 1.17 6.9 ± 0.22 39.1 ± 1.02
PLT :  platelet, WBC :  white blood cell, RBC :  red blood cell, Hct :  hematocrit
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relative to the control group.  In addition, the changes in the time interval were larger in 
EDTA-treated blood than in heparin-treated blood.
The effects of adrenergic drugs added directly to the blood samples in vitro
　Heparin was used to prevent blood coagulation in these in vitro experiments.  The 
time interval for the control group was 52.98 ± 3.86 s, for the 10×α-AR agonist-treated 
group was 58.86 ± 4.79 s, for the 10×β-AR agonist-treated group was 48.23±4.14 s （Fig. 
2A）.  The α-AR agonist significantly increased the time interval and the β-AR agonist 
signicantly decreased the time interval relative to the control group.  These results were in 
agreement with the results for the i.p. agonist administration.  The in vitro addition of α- 
AR or β-AR  antagonist had no effect on blood uidity （Fig. 2B）.
The effects of adrenergic drugs on Plt aggregation using the LS method
The effects of i.p. administered adrenergic drugs
　Citrate was used to prevent blood coagulation in these experiments.  The proportion of 
Fig. 1.  The effects of intraperitoneally administered adrenergic drugs on blood uidity measured by MC-FAN.
Heparin was added as anticoagulant in A and B. EDTA was added as anticoagulant in C and D.
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small aggregate was 34.00±0.82 ％ for the β-AR agonist-treated group, which was signi-
cantly larger than the 30.50±1.73％ observed for the control group （Fig. 3A）.  The propor-
tion of medium aggregate was 28.00±0.50％ for the α-AR agonist-treated group, which 
was smaller than 28.75±0.82％ in the control group.  The proportion of large aggregate 
was 31.75 ± 0.82％ for the α-AR agonist-treated group, which was smaller than the 34.00±
0.82％ observed for the control group （Fig. 3A）.  The proportion of large aggregate was 
34.75 ± 1.71％ for the β-AR agonist-treated group, which was larger than the 34.00±0.82％ 
observed for the control group.
The effects of adrenergic drugs added directly into the blood samples in vitro
　Citrate was used to prevent blood coagulation in these experiments.  There was no effect 
on Plt aggregation for either α-AR or β-AR agonist when added directly to blood （Fig. 
3B）.
Fig. 2.  The direct effects of adrenergic drugs on blood uidity of sampled blood measured by MC-FAN.
Fig. 3.   The effects of adrenergic drugs on platelet aggregation ability measured using the novel light scattering 
method with PA-20.
Adrenergic drugs were intraperitoneally administered in A, and were directly added into test tubes containing 
sampled blood in B.
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The effects of adrenergic drugs on Plt aggregation using the LT method
The effects of i.p. administered adrenergic drugs
　The turbidity ratio between the PRP and PPP samples was signicantly increased for the 
α-AR agonist-treated group and was signicantly decreased for the β-AR agonist-treated 
group （Fig. 4A）.
In vitro experiment
　We observed a tendency for the turbidity ratio to be increased for the α-AR agonist-
treated group and to be decreased for the β-AR agonist-treated group, but there was no 
statistical signicance （Fig. 4B）.  In vitro addition of α-AR agonist alone or β-AR agonist 
alone did not affect the turbidity ratio of PRP to PPP （Fig. 4C）.
Discussion
　Many factors can contribute to cardiovascular disorders but blood uidity is one factor 
that has not been examined in detail.  A reduction in blood uidity results in an increase 
in blood vessel resistance according to Poiseuille’s law, which in turn results in an increase 
in blood pressure 8, 9）.  Furthermore, a reduction in blood uidity enhances blood coagulation, 
which increases the risks of thrombosis, ischemic heart disease, and cerebrovascular disorders. 
It has been established that many psychological and physical stressors can cause cardiovascu-
lar disorders through both neuronal and humoral mechanisms.  The effects of these stressors 
on blood uidity remain poorly understood.  We have already reported that restriction or 
electrical shock stress reduces blood uidity 10, 11） and the sympathetic nervous system and 
pituitary-adrenal axis have been implicated in the mechanisms through which these stressors 
affect blood uidity.  Therefore, we examined the effects of adrenergic agonists and antago-
Fig. 4.   The effects of adrenergic drugs on platelet aggregation ability by the conventional light transmission 
method with PA-20.
Trans （％） indicates the difference in the transmission intensity for the PRP and PPP samples expressed as 
a percentage. ADP was added as an initiator of platelet aggregation in A and B, but was not added in C.　
Adrenergic drugs were administered intraperitoneally in A, and were added in vitro in B and C.
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nists on blood uidity in this study.
　Blood uidity is controlled by components such as RBCs, WBCs, Plts and is affected by 
plasma proteins, glucose concentration, transported lipids12, 13）, inammatory mediators14）, and 
cytokines.  An increase in the hematocrit, reduced RBC deformability11）, increased WBC 
adhesion15, 16）, and increased Plt aggregation will all result in increased vessel resistance17, 18）.
　The numbers of RBCs, WBCs, Plts, and the hematocrit did not demonstrate any statistical-
ly signicant difference between the control and experimental groups （Table 1）.  These data 
suggest that blood cell number is independent of the changes in blood uidity produced by 
adrenergic agonists and antagonists.
　In vivo administration of α-AR antagonist and β-AR agonist enhanced blood fluidity 
whereas, α-AR agonist and β-AR antagonist reduced blood uidity （Fig. 1）.  These data 
indicate that activation of α-AR reduces blood uidity and activation of β-AR increases it. 
In addition, the existence of tonic adrenergic action was suggested because the adrenergic 
antagonists affected blood uidity.
　When adrenergic drugs were directly administered to the sampled blood, the blood uidity 
was decreased by α-AR agonist and increased by β-AR agonist （Fig. 2）.  This indicates 
that endogenous catecholamines may directly affect the blood uidity, since the direction of 
action was same as for the i.p. administered adrenergics.  On the other hand, the adrenergic 
antagonists did not affect blood uidity, which indicates that there is no tonic adrenergic 
action in the sampled blood.
　When heparin is administered, it combines with antithrombin and inhibits activity of 
thrombin, and coagulation factor Xa and XIIa but does not inhibit Plt aggregation directly. 
EDTA chelates calcium ions and thereby inhibits blood coagulation, WBC adhesion, and Plt 
aggregation.  When heparin is used as the anticoagulant, Plt aggregation, RBC deformability, 
and WBC adhesion can all affect blood uidity.  On the other hand, when EDTA is used 
as the anticoagulant, RBC deformability affects blood fluidity predominantly, because Plt 
aggregation and WBC adhesion are blocked.  Therefore, we observed that blood uidity is 
affected by adrenergic agonists and antagonists regardless of the use of heparin or EDTA as 
an anticoagulant.  This indicates that adrenergics affect blood uidity through both mecha-
nisms of RBC deformability and Plt aggregation.  Our data shows that the hematocrit and 
RBC number do not inuence blood uidity （Table 1）.
　We used the PA-20 to measure Plt aggregation directly and showed that systemic α-AR 
agonist increased the number of large aggregates of Plt （Fig. 3A） and the turbidity of PRP 
（Fig. 4A）.  Systemic β-AR agonist decreased large aggregates （Fig. 3A） and turbidity （Fig. 
4A）, but adrenergic drugs added directly to blood did not have any effect on Plt aggrega-
tion （Figs. 3B, 4B）.  Our data suggests that adrenergic agonists may affect Plt aggregation 
through the autonomic nervous system or the pituitary-adrenal axis, but not through a direct 
action on the blood.  Human Plts express ARs and form aggregates when treated with 
adrenergic drugs directly, but rodent Plt do not aggregate when treated similarly （Fig. 4C）.
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　Therefore, we propose that the ability of Plts to aggregate is induced when α-AR agonist 
decreases blood fluidity, and is repressed when β-AR agonist increases blood fluidity.  When 
adrenergic drugs were added to the blood directly, there was a tendency to affect Plt aggregation 
but there was no signicant difference between control group and experimental group （Fig. 3B）. 
　In conclusion, we have shown that the adrenergic α-AR system decreases blood uidity 
and the β-AR system increases blood uidity through RBC deformability and Plt aggrega-
tion ability, and that the adrenergic system is functioning tonically.
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